[go: up one dir, main page]

WO2008031835A3 - Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf - Google Patents

Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf Download PDF

Info

Publication number
WO2008031835A3
WO2008031835A3 PCT/EP2007/059559 EP2007059559W WO2008031835A3 WO 2008031835 A3 WO2008031835 A3 WO 2008031835A3 EP 2007059559 W EP2007059559 W EP 2007059559W WO 2008031835 A3 WO2008031835 A3 WO 2008031835A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
autoimmune disease
autoimmune diseases
pathway inhibitors
treating autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/059559
Other languages
English (en)
Other versions
WO2008031835A2 (fr
Inventor
Peter C Hiestand
Christian Schnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of WO2008031835A2 publication Critical patent/WO2008031835A2/fr
Publication of WO2008031835A3 publication Critical patent/WO2008031835A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode permettant de traiter un animal à sang chaud atteint d'une maladie auto-immune, telle que la sclérose en plaques, une névrite périphérique, une névrite optique, la sclérose latérale amyotrophique ou une uvéite. La méthode selon l'invention consiste à administrer audit animal une dose thérapeutiquement efficace d'un inhibiteur de la voie VEGF, par exemple Bevacizumab, Sunitinib or Sorafenib, seule ou en combinaison avec d'autres mesures thérapeutiques. L'invention a également trait à l'utilisation d'un inhibiteur de la voie VEGF pour préparer un médicament destiné à traiter une maladie auto-immune, et à un emballage commercial contenant un tel médicament ainsi que des instructions d'utilisation associées dans le cadre du traitement d'une maladie auto-immune.
PCT/EP2007/059559 2006-09-13 2007-09-12 Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf Ceased WO2008031835A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120606 2006-09-13
EP06120606.6 2006-09-13

Publications (2)

Publication Number Publication Date
WO2008031835A2 WO2008031835A2 (fr) 2008-03-20
WO2008031835A3 true WO2008031835A3 (fr) 2008-05-22

Family

ID=37726915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/059559 Ceased WO2008031835A2 (fr) 2006-09-13 2007-09-12 Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf

Country Status (1)

Country Link
WO (1) WO2008031835A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005527A1 (fr) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Traitement de maladies oculaires et d’une néovascularisation excessive utilisant un traitement combiné
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
US20110112121A1 (en) * 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
EP2611437B1 (fr) 2010-09-02 2017-03-29 Kyoto University Composition pharmaceutique destinée à la prévention et au traitement de la sclérose latérale amyotrophique
RU2523146C1 (ru) * 2013-04-08 2014-07-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения монокулярного оптического неврита при рассеянном склерозе
SG11201705767PA (en) * 2015-01-13 2017-08-30 Univ Kyoto Agent for preventing and/or treating amyotrophic lateral sclerosis
EP3414330A4 (fr) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. Compositions à demi-vie intravitréenne améliorée et leurs utilisations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
WO2005009367A2 (fr) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Traitement de maladies au moyen d'inhibiteurs de kinase
WO2006020145A2 (fr) * 2004-07-19 2006-02-23 The Johns Hopkins University Inhibiteurs de flt3 a des fins d'immunodepression
WO2006059234A2 (fr) * 2004-09-15 2006-06-08 Novartis Ag Amides bicycliques comme inhibiteurs de kinases
US20060134111A1 (en) * 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
WO2005009367A2 (fr) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Traitement de maladies au moyen d'inhibiteurs de kinase
WO2006020145A2 (fr) * 2004-07-19 2006-02-23 The Johns Hopkins University Inhibiteurs de flt3 a des fins d'immunodepression
WO2006059234A2 (fr) * 2004-09-15 2006-06-08 Novartis Ag Amides bicycliques comme inhibiteurs de kinases
US20060134111A1 (en) * 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FISHER WILSON J: "Angiogenesis therapy moves beyond cancer", ANNALS OF INTERNAL MEDICINE, NEW YORK, NY, US, vol. 141, no. 2, 20 July 2004 (2004-07-20), pages 165 - 168, XP002378544, ISSN: 0003-4819 *
MANLEY P W ET AL: "Therapies directed at vascular endothelial growth factor", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 11, no. 12, December 2002 (2002-12-01), pages 1715 - 1736, XP002256125, ISSN: 1354-3784 *

Also Published As

Publication number Publication date
WO2008031835A2 (fr) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
WO2007138466A3 (fr) Compositions pharmaceutiques comprenant une combinaison de meloxicam et de tramadol
WO2006093348A3 (fr) Procede et composition destines au traitement des maladies vasculaires peripheriques
WO2008050329A3 (fr) NOUVEAUX ARNsi ET PROCÉDÉS D'UTILISATION DE CEUX-CI
WO2008022256A3 (fr) Procédés et compositions de prévention ou de traitement de maladies liées au vieillissement
WO2008076847A3 (fr) Délivrance régionale d'agents thérapeutiques pour le traitement de maladies vasculaires
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
WO2009093119A3 (fr) Utilisation d'inhibiteurs de sérine protéases pour traiter des maladies de peau
WO2013003629A3 (fr) Procédés et compositions visant à inhiber la résorption osseuse
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
WO2008031835A3 (fr) Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf
WO2009109613A3 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1, cx3cr1 et p40
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MY168763A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
WO2009109616A3 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l'expression de mcp-1, cx3cr1 et p40
WO2006029036A3 (fr) Therapie combinee avec du glatiramere acetate et de la n-acetylcysteine pour traiter la sclerose en plaques
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
MX2012001708A (es) Anticuerpo humanizado anti-oligomero de amiloide b.
WO2008070010A3 (fr) Rétablissement après une attaque
MX2009011900A (es) Curacion de herida diabetica.
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
WO2008012796A3 (fr) Compositions pharmaceutiques comprenant ccl2 et leur utilisation dans le traitement d'une inflammation
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
MX2014002480A (es) Uso del compuesto organico para el tratamiento del sindrome de noonan.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07803423

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07803423

Country of ref document: EP

Kind code of ref document: A2